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Abst rac t - -A  logistic model of periodic chemotherapy is developed that includes drug resistance. 
Criteria are developed to describe the acceptable number of doses before tumor regrowth due to drug 
resistance occurs. The model is then compared with some clinical results, and it is shown that they 
qualitatively match well. 
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1. INTRODUCTION 
The effects of drug resistance are investigated by extending the logistic model of periodic chemo- 
therapy examined in [1]. This is done by altering the term in the logistic equation that describes 
the chemotherapeutic effects to a decreasing function of time and/or dose. (A similar model by 
Usher [2] w i thout  drug resistance considers the logistic growth model, along with some variations 
to it, with constant  chemotherapeutic effects.) More specifically, if the term representing the 
chemotherapeutic effects is a decreasing function of time, then it describes acquired resistance 
(due to random mutations in cancer cells), while if the term is a decreasing function of dose, then it 
describes induced resistance (resistance induced by the chemotherapeutic drugs). The magnitude 
of induced resistance typically ranges from each dose inducing approximately 1% to 50% of the 
drug-sensitive c lls to a resistant state, while in the acquired resistance case approximately 10 -3  to 
10 -6 cells per unit time become resistant. By understanding the kinetic effects of drug resistance, 
we are able to derive basic criteria to determine how many effective doses of a particular drug 
or combination of drugs can be administered before the tumor mass can no longer be reduced 
because a majority of the cells are resistant o the drug regimen. This number of doses is known 
as the NADIR. We are then able to compare this model to some clinical results given by [3] and 
find that they qualitatively match. 
2. THE MODEL 
We use the logistic growth model to describe the growth of the tumor mass y(t), and we model 
the effects of the chemotherapeutic drugs by periodically varying the growth rate of the tumor 
mass. Note that for the dose to have negative effects on the tumor, it will have to cause the 
growth rate to be negative for a period of time over each dose. The model in this paper is in the 
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following form: 
dy(t) = ry(t) 1 - bi(t) di(n, t) - , nr < t < (n + 1)r. (1) 
dt i=1 
These parameters are defined as follows: r is the growth rate of the tumor mass in the absence 
of any chemotherapy, bi(t) is the periodic effects of drug i, n is the dose number, d~(n, t) is the 
effects of resistance caused by drug i (note that this is a decreasing function), K is the carrying 
capacity, and ~- is the length of each dose. Some forms for bi(t) are 
f bi, nT < t < a~ + nT,  
bi(t) 
O, ai -~- nT < t < (n + 1)r, (2) 
bi(t) = bie -a'(t-nr),  nr  < t < (n + I)T, (3) 
bi (e -a'(t-nr) - e-C'(t -nr)) ,  aT < t < (n+ 1)T, Ci > b~(t) (4) a i ,  
where equation (2) is the step function, which has constant effects for the first part of the period, 
and then no effects for the second part of the period; equation (3) is the exponential function, 
which initially has strong effects that decay off exponentially; and equation (4) is the modified 
exponential function, which has minimal effects initially, but quickly increases exponentially 
before it then starts to decay exponentially. We will consider di(n, t) to be just a function of n 
(i.e., dose), thus only considering induced resistance. Two forms that we will consider are 
1 
di(n) - < 1, 7i, n > 0, (5) 
7in + 1 - 
1 
d~(n) = 2~----- ~ < 1, 7i, n > O. (6) 
Note that at n = 0 (the first dose), there are no resistant effects, but as n increases, di(n) 
decreases, and when multiplied by bi(t), the effectiveness of the drug is reduced. For equation (6), 
the parameter 7i can directly relate to the percent of induced resistant cells per dose (call this 
ai), i.e., 
in (1 - (r) 
7i - in 2 
Therefore, if ai = 0.5 (50% of cancer cells induced per dose), then 7i = 1, and if ai = 0.01 (1% 
of cancer cells induced per dose), then 7 /~ 0.0145. 
Scaling the model to eliminate K, we let y(t) = Kx( t )  to obtain 
(ira ] ) dx(t) = rx(t)  1 - Eb i ( t )  di(n) - x(t) , 
dt i=1 
n~- < t < (n + 1)T. (S) 
Note this simplifies to the model in [1], when di(n) -- 1 (no resistance) and i --- 1 (only one drug). 
3. SOLUTIONS 
As noted in [1], equation (8) is a Bernoulli-type differential equation and can be solved exactly. 
The solution is 
rF  ~ [1--~ -~m b~(s) d~(n)]ds 
Xo e .1 t z..~=l 
x(t) = f ,  (9) 
1 + (xo / r ) f te  ~ [1-~,=,b~(¢)d~(')]dCds 
Again, using this solution and the fact that bi(t) is periodic with period ~-, we can set up a 
difference quation that describes the state of the cancer cells at the beginning of each period. 
Equation (9) describes the growth of the tissue over each period, where x0 is the cell mass at the 
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beginning of the period. The resulting difference quation that describes the state of the tumor 
mass after n doses is 
F(ngl ) r  rn 
r [*- b, ( , )  es 
XnTe ~nT 
x(~+l)r = [(~+1), " (10) 
1 + (xn./r) n T err  
As in [1], we determine the two equilibria of equation (10) to be 
X~q = 0, (11) 
Xeq= / (n+l)r  r f "  m (12) ~,  e [1 -E i : l  bi({)di(n)] d( d8  
Next, we define 
1/0  (bi(t)> =- - b,(t) dt (13) 
T 
as the mean value of bi(t). 
We now define a condition that describes decay of the tumor mass (i.e., when the characteristic 
nmltiplier of (10) is less than one). This occurs when 
or 
~-~<bi(t)>di(n) > I. (14) 
i=1 
Unlike the model with no resistance, condition (14) will only hold for a finite number of doses 
because of the resistant erm di(n) (unless there exists a noneross-resistant drug, i.e., di(n) - 1 
for some i). Thus, the cancer mass will be able to recur when condition (14) becomes less than 
one. The number of doses to get to this point is the NADIR. 
4. NADIR  FOR STEP  FUNCTION 
Consider the special case where bi(t) is in the form (2) and di(n) is of the form (5) and (6), 
respectively. Also consider using just one chemotherapeutic drug (i.e., i = 1). Condition (14) 
then becomes 
1 
- - a l b  1 > 7., 
71n+ 1 
1 
2%nalbl > 7", 
respectively. Solving for n in each case, we get 
i.e., 
albl -- 7" 
n < - - ,  (15) 
3'17" 
lnalbl  - ln r  
n< ln (1 -c t l )  ' (16) 
respectively. 
tumor and only have a detrimental effect on the other normal tissues surrounding the tumor. 
Similar calculations can easily be made in the case of b~(t) in the form of (3) or (4). 
NADIR = Integer part \( alb~ --717. ") , (17) 
( In_alb1-1nT"h (18) 
NADIR - Integer part \ in (1 - c~z) / ' 
Therefore, doses exceeding (17) or (18) will not continue to reduce the size of the 
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5. RESULTS 
As can be seen from equations (17) and (18) (and in similar results in the other cases), the 
major parameters given by this model for determining drug effectiveness are the period and 
the strength of the drug (ai, bi,7), and the degree of resistance (Vi or ~i). Note that the 
parameter r (growth rate) does not factor in directly, but only indirectly through the parameters 
ai and bi. 
The NADIR condition (18) can be very useful because it allows us to calculate the degree of 
resistance (ai) for a specific drug or combination of drugs. That is, given the known information of 
period, strength of dose, and NADIR, we can calculate ai. Once ai is known for a particular drug 
or combination of drugs, we can then determine the best method of delivering the chemotherapy 
to allow for the greatest tumor reduction. 
For a basic model of resistance, this fits very well to actual data given in [3]. Compare Figure 1 
with graphs of data in [3]. They both follow the same qualitative form, and given the correct 
choice of parameters, the model can predict the NADIR of the given drug regimen. 
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F igure  1. Tumor  mass  vs. t ime.  
6. CONCLUSIONS 
This model takes an implicit view of drug resistance. That is, it does not directly examine 
the sensitive and resistant cancer cells as two different "compartments," but rather models the 
resistance as a decaying drug effect. Models such as those in [4-7] consider an explicit view of 
drug resistance by considering two or more compartment models where each compartment models 
a specific type of cancer cell. 
This model shows that even with a general equation such as logistic growth, we can qualita- 
tively match clinical results. This can help give us a better idea on how resistance is affecting the 
chemotherapeutic regimens. It also helps us determine which mathematical parameters, thus clin- 
ical parameters, affects the success or failure of the drug regimen, along with how the parameters 
affect each other. 
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